The effect of histone deacetylase inhibitors on the bone environment in multiple myeloma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1070880

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Multiple myeloma (MM) is an incurable hematological malignancy with 1,400 people diagnosed each year. Severe bone loss occurs in up to 90% of these patientssignificantly impacting on quality of life resulting in severe bone pain and bone lesions that fail to heal. This project proposes that a novel histone deacetylase inhibitor could provide an appropriate therapeutic strategy that inhibits tumor growth and prevents bone loss whilst also promoting bone repair.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2021

Funding Scheme: Early Career Fellowships

Funding Amount: $356,899.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anticancer drug | bone formation | bone loss | histone deacetylase | multiple myeloma

Related Links